Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration

Heather K Knych, C. R. Corado, D. S. Mckemie, E. Scholtz, R. Sams

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tramadol is a synthetic opioid used in human medicine, and to a lesser extent in veterinary medicine, for the treatment of both acute and chronic pain. In humans, the analgesic effects are owing to the actions of both the parent compound and an active metabolite (M1). The goal of the current study was to extend current knowledge of the pharmacokinetics of tramadol and M1 following oral administration of three doses of tramadol to horses. A total of nine healthy adult horses received a single oral administration of 3, 6, and 9 mg/kg of tramadol via nasogastric tube. Blood samples were collected at time 0 and at various times up to 96 h after drug administration. Urine samples were collected until 120 h after administration. Plasma and urine samples were analyzed using liquid chromatography-mass spectrometry, and the resulting data analyzed using noncompartmental analysis. For the 3, 6, and 9 mg/kg dose groups, Cmax, Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively. While tramadol and M1 plasma concentrations within the analgesic range for humans were attained in the 3 and 6 mg/kg dose group, these concentrations were at the lower end of the analgesic range and were only transiently maintained. Furthermore, until effective analgesic plasma concentrations have been established in horses, tramadol should be cautiously recommended for control of pain in horses. No significant undesirable behavioral or physiologic effects were noted at any of the doses administered.

Original languageEnglish (US)
Pages (from-to)389-398
Number of pages10
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume36
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Tramadol
pharmacology
oral administration
pharmacokinetics
Horses
Oral Administration
analgesics
Pharmacokinetics
horses
Analgesics
pain
urine
dosage
analgesic effect
administered dose
enteral feeding
narcotics
sampling
Urine
liquid chromatography

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. / Knych, Heather K; Corado, C. R.; Mckemie, D. S.; Scholtz, E.; Sams, R.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 36, No. 4, 08.2013, p. 389-398.

Research output: Contribution to journalArticle

Knych, Heather K ; Corado, C. R. ; Mckemie, D. S. ; Scholtz, E. ; Sams, R. / Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. In: Journal of Veterinary Pharmacology and Therapeutics. 2013 ; Vol. 36, No. 4. pp. 389-398.
@article{c21b05395c2e41c0a657526afe79c401,
title = "Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration",
abstract = "Tramadol is a synthetic opioid used in human medicine, and to a lesser extent in veterinary medicine, for the treatment of both acute and chronic pain. In humans, the analgesic effects are owing to the actions of both the parent compound and an active metabolite (M1). The goal of the current study was to extend current knowledge of the pharmacokinetics of tramadol and M1 following oral administration of three doses of tramadol to horses. A total of nine healthy adult horses received a single oral administration of 3, 6, and 9 mg/kg of tramadol via nasogastric tube. Blood samples were collected at time 0 and at various times up to 96 h after drug administration. Urine samples were collected until 120 h after administration. Plasma and urine samples were analyzed using liquid chromatography-mass spectrometry, and the resulting data analyzed using noncompartmental analysis. For the 3, 6, and 9 mg/kg dose groups, Cmax, Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively. While tramadol and M1 plasma concentrations within the analgesic range for humans were attained in the 3 and 6 mg/kg dose group, these concentrations were at the lower end of the analgesic range and were only transiently maintained. Furthermore, until effective analgesic plasma concentrations have been established in horses, tramadol should be cautiously recommended for control of pain in horses. No significant undesirable behavioral or physiologic effects were noted at any of the doses administered.",
author = "Knych, {Heather K} and Corado, {C. R.} and Mckemie, {D. S.} and E. Scholtz and R. Sams",
year = "2013",
month = "8",
doi = "10.1111/jvp.12009",
language = "English (US)",
volume = "36",
pages = "389--398",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration

AU - Knych, Heather K

AU - Corado, C. R.

AU - Mckemie, D. S.

AU - Scholtz, E.

AU - Sams, R.

PY - 2013/8

Y1 - 2013/8

N2 - Tramadol is a synthetic opioid used in human medicine, and to a lesser extent in veterinary medicine, for the treatment of both acute and chronic pain. In humans, the analgesic effects are owing to the actions of both the parent compound and an active metabolite (M1). The goal of the current study was to extend current knowledge of the pharmacokinetics of tramadol and M1 following oral administration of three doses of tramadol to horses. A total of nine healthy adult horses received a single oral administration of 3, 6, and 9 mg/kg of tramadol via nasogastric tube. Blood samples were collected at time 0 and at various times up to 96 h after drug administration. Urine samples were collected until 120 h after administration. Plasma and urine samples were analyzed using liquid chromatography-mass spectrometry, and the resulting data analyzed using noncompartmental analysis. For the 3, 6, and 9 mg/kg dose groups, Cmax, Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively. While tramadol and M1 plasma concentrations within the analgesic range for humans were attained in the 3 and 6 mg/kg dose group, these concentrations were at the lower end of the analgesic range and were only transiently maintained. Furthermore, until effective analgesic plasma concentrations have been established in horses, tramadol should be cautiously recommended for control of pain in horses. No significant undesirable behavioral or physiologic effects were noted at any of the doses administered.

AB - Tramadol is a synthetic opioid used in human medicine, and to a lesser extent in veterinary medicine, for the treatment of both acute and chronic pain. In humans, the analgesic effects are owing to the actions of both the parent compound and an active metabolite (M1). The goal of the current study was to extend current knowledge of the pharmacokinetics of tramadol and M1 following oral administration of three doses of tramadol to horses. A total of nine healthy adult horses received a single oral administration of 3, 6, and 9 mg/kg of tramadol via nasogastric tube. Blood samples were collected at time 0 and at various times up to 96 h after drug administration. Urine samples were collected until 120 h after administration. Plasma and urine samples were analyzed using liquid chromatography-mass spectrometry, and the resulting data analyzed using noncompartmental analysis. For the 3, 6, and 9 mg/kg dose groups, Cmax, Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively. While tramadol and M1 plasma concentrations within the analgesic range for humans were attained in the 3 and 6 mg/kg dose group, these concentrations were at the lower end of the analgesic range and were only transiently maintained. Furthermore, until effective analgesic plasma concentrations have been established in horses, tramadol should be cautiously recommended for control of pain in horses. No significant undesirable behavioral or physiologic effects were noted at any of the doses administered.

UR - http://www.scopus.com/inward/record.url?scp=84880042480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880042480&partnerID=8YFLogxK

U2 - 10.1111/jvp.12009

DO - 10.1111/jvp.12009

M3 - Article

VL - 36

SP - 389

EP - 398

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 4

ER -